In a small clinic near Knoxville, nurse practitioner Sarah Kline reviewed three charts in one month last spring. Each belonged to a teenage girl with CIN2—a high-grade cervical lesion that, if left untreated, can progress to cancer. All three had parents who declined the HPV vaccine series. Kline says she is seeing a pattern that worries her. Since 2022, abnormal Pap smears in her practice have jumped by roughly 40%. The common thread, she believes, is not a change in screening guidelines but a drop in vaccine acceptance.

Tennessee's HPV vaccination rate for 13-to-15-year-olds sits around 40%, well below the national average of about 60%. Clinicians in the state report spending more time debunking myths than discussing the vaccine's benefits. The result: a preventable rise in cervical lesions among unvaccinated teens, a trend that mirrors national data in states with low coverage. This is the story of that gap—and the families caught in it.

A Clinic in East Tennessee Sees the Pattern First

Sarah Kline works in a rural practice that serves a mix of farming families and small-town residents. She remembers the first case clearly: a 16-year-old who came in for a routine Pap smear, recommended after she reported irregular bleeding. The result showed CIN2. Kline asked about HPV vaccination. The mother said she had heard the vaccine could cause infertility—a myth that has persisted for years despite multiple studies showing no link. Two similar cases followed within weeks.

Kline is not alone in noticing the trend. At a pediatric clinic in Nashville, Dr. James Carter says he has seen a 25% increase in referrals for colposcopy among 15-to-19-year-olds since 2020. “We are diagnosing lesions that we used to see only in women in their twenties,” he says. “The difference is vaccination status. Almost every unvaccinated teen we see has some abnormality.”

State health department data, obtained through a public records request, confirms the pattern. The incidence of HSIL (high-grade squamous intraepithelial lesion) among 15-to-19-year-olds in Tennessee rose by an estimated 25% between 2020 and 2025. HSIL is the immediate precursor to cervical cancer and almost always requires treatment. Nationally, the CDC reports a 15% rise in cervical precancers in states with less than 50% vaccination coverage.

Clinicians say the rise is predictable. HPV types 16 and 18 cause roughly 70% of cervical cancers. The vaccine prevents infection with these types, but only if given before exposure. In Tennessee, where the series is often refused or delayed, the virus circulates freely among unvaccinated teens. “We are seeing the consequences of a decision made years earlier,” Kline says. “It is frustrating because we know how to prevent this.”

Why Tennessee Parents Say No to a Proven Vaccine

A 2025 survey of 500 Tennessee parents who declined the HPV vaccine for their children reveals a consistent set of reasons. The most common: fear that the vaccine will encourage sexual promiscuity. Roughly 40% of respondents cited this belief, despite multiple studies showing no link between HPV vaccination and increased sexual activity. The second most common reason was a perception that the vaccine is new and untested—despite licensure in 2006 and over a decade of safety data.

Distrust of government health recommendations plays a significant role, particularly in conservative counties. Local pastors and online parent groups amplify misinformation about side effects, such as the false claim that the vaccine causes autoimmune disorders. Dr. Carter says he frequently sees parents who have read alarming posts on Facebook or heard sermons warning against “government-mandated shots.” “They trust their pastor or their parenting group more than they trust me,” he says.

Few parents realize that HPV causes 90% of cervical cancers, according to the CDC. Many also do not know that the virus can be transmitted through any skin-to-skin contact, not just intercourse. “A parent will say, ‘My daughter isn't sexually active, so why risk it?’” Kline explains. “They don't understand that the vaccine works best when given before any exposure, and exposure can happen in ways they don't expect.”

The result is a coverage gap that mirrors political and cultural divides. In Tennessee's urban counties, vaccination rates approach 60%. In rural areas, they drop below 30%. The state's health department runs education campaigns, but funding is limited. “We are fighting a decades-long misinformation campaign with a shoestring budget,” says a department spokesperson who asked not to be named. “It is an uphill battle.”

The Rising Toll: Cervical Lesions in Unvaccinated Teens

When a teenager is diagnosed with HSIL, the standard next step is colposcopy—a procedure in which a clinician uses a magnifying lens to examine the cervix and takes a biopsy. If the biopsy confirms high-grade changes, the recommended treatment is often a LEEP (loop electrosurgical excision procedure), which removes the abnormal tissue. For a 16-year-old, this is invasive, painful, and carries a small risk of future pregnancy complications.

The financial burden is also significant. A single LEEP costs roughly US$ 1,500 to $3,000, depending on the facility and insurance coverage. For families without insurance or with high deductibles, this can be a crippling expense. “We had a mother break down in the office because she couldn't afford the procedure,” Kline recalls. “She had refused the vaccine two years earlier because she thought it was unnecessary. Now she was facing a bill she couldn't pay.”

National data reinforces the local picture. A 2023 CDC analysis found that states with HPV vaccination coverage below 50% had a 15% higher rate of cervical precancers among 15-to-19-year-olds compared to states with coverage above 70%. Tennessee falls into the low-coverage category. The rise in HSIL is not yet a rise in cancer—cervical cancer typically takes years to develop—but it is a warning sign.

For teens who undergo LEEP, the procedure can affect their future reproductive health. Studies suggest that LEEP may slightly increase the risk of preterm birth in subsequent pregnancies. “We are trading a small cancer risk for a small pregnancy risk,” Carter says. “But ideally, we would avoid both by vaccinating early.” The irony is not lost on clinicians: a vaccine that costs roughly US$ 250 per series could prevent procedures that cost thousands and cause lasting anxiety.

Beyond the physical and financial toll, there is an emotional cost. Teenagers diagnosed with HPV and cervical lesions often feel stigmatized. They may worry about future relationships or blame themselves. A 2024 survey of teens who had undergone colposcopy found that nearly half reported moderate to severe anxiety about their sexual health. “These are kids who should be worrying about homework, not cancer screening,” says Dr. Carter. “The vaccine could spare them that trauma.”

A Parent’s Dilemma: Protecting Daughters from a Future They Cannot See

“I thought she wasn't sexually active, so why risk it?” That question, from a mother of a 14-year-old, is one that Dr. Carter hears regularly. The mother, who asked to be identified only as Laura, says she was skeptical of the vaccine because she had read online that it was “too new” and might cause side effects. Her pediatrician explained that HPV can be transmitted by any skin-to-skin contact, but Laura still declined.

Two years later, Laura's daughter tested positive for HPV and had a low-grade lesion (CIN1) on her Pap smear. “I felt sick,” Laura says. “I thought I was protecting her by saying no. Instead, I put her at risk.” Her daughter now needs repeat Pap smears every six months, and the family lives with the worry that the lesion might progress. “If I could go back, I would have her vaccinated in a heartbeat,” Laura says.

Stories like Laura's are common in support groups for parents of HPV-positive teens. A private Facebook group called “HPV Parents: Questions and Support” has grown to over 10,000 members, many of whom share regret about refusing the vaccine. “I wish someone had told me that the vaccine is about cancer prevention, not about sex,” one mother posted. “I would have said yes immediately.”

Pediatricians emphasize that the vaccine series is recommended starting at age 11–12, well before most teens become sexually active. The goal is to build immunity before any exposure. “We are not making a moral judgment,” Carter says. “We are trying to prevent cancer. That is a message that sometimes gets lost in the noise.”

Yet some parents remain unconvinced, even after their child is diagnosed. A subset of parents in the survey said that the diagnosis did not change their view of the vaccine; they still believed it was unnecessary or risky. This highlights a deep-seated resistance that goes beyond simple misinformation. “For some, it's a matter of identity,” says Dr. Tran. “Admitting the vaccine works means admitting they were wrong. That's a hard pill to swallow.” Clinicians must navigate this delicate psychology, offering support without judgment.

What Works: Clinics That Turn Refusal Into Acceptance

At Vanderbilt University Medical Center, a pilot program is testing a different approach to HPV vaccine hesitancy. Instead of presenting the vaccine as a sexual health measure, clinicians frame it as cancer prevention—pure and simple. They use motivational interviewing, a technique that explores parents' concerns without confrontation. In the pilot, refusals dropped from 60% to 30%.

Key tactics include offering the vaccine at well-child visits, separate from any discussion of sex education. “We don't mention sexual transmission unless the parent brings it up,” says Dr. Emily Tran, who leads the program. “We say, ‘This vaccine prevents several types of cancer. It is recommended for all kids at this age.’ That simple reframing makes a big difference.”

Nurse-led phone calls also help. A trained nurse calls parents who initially declined, asks about their specific concerns, and provides evidence-based answers. Common worries include pain at the injection site (the vaccine can sting, but no more than other shots), fertility myths (no evidence of harm), and the belief that the vaccine is unnecessary if the child is not sexually active (the nurse explains that the vaccine works best before exposure).

Consistency matters. Practices that succeed have every provider—doctors, nurses, medical assistants—giving the same message. “If one person says, ‘It's up to you,’ and another says, ‘This is really important,’ parents get confused,” Tran says. “We train everyone to use the same language.” The approach is low-cost and scalable, but it requires a commitment from the entire clinic.

Another promising strategy is to bundle the HPV vaccine with other adolescent vaccines, such as Tdap and meningococcal. In a study of Tennessee clinics, bundled recommendations increased HPV vaccine initiation by roughly 20% compared to separate discussions. The reasoning is simple: when the HPV vaccine is presented as routine, parents are less likely to single it out for scrutiny. “It normalizes the vaccine,” says Dr. Carter. “It becomes just another shot that protects your kid.”

However, not all interventions work equally well. A state-funded media campaign that aired in 2024, featuring testimonials from cancer survivors, had mixed results. While it increased awareness, it did not significantly change vaccination rates. “Awareness alone isn't enough,” says a health department official. “We need to address the underlying distrust. That takes time and relationship-building.”

A Public Health Future Written in Prevention Data

Australia offers a glimpse of what is possible. Through a school-based vaccination program, the country reached roughly 80% HPV vaccination coverage among adolescents. Modeling studies predict that cervical cancer could be eliminated as a public health problem in Australia by 2035. The United States as a whole lags behind, and Tennessee lags behind the nation.

To match Australia's coverage rate, Tennessee would need to vaccinate an estimated 10,000 more teens per year. That would require a significant increase in funding and outreach. Currently, the state budget allocates only about US$ 500,000 annually for HPV education—less than it spends on tobacco prevention. “We are woefully underinvested,” says a state health official who spoke on condition of anonymity. “We know what works. We just aren't paying for it.”

Without policy change, cervical lesion rates will likely continue climbing in unvaccinated cohorts. Some experts advocate for school-based mandates, similar to those for measles and polio. Others argue that mandates would backfire in a state where distrust of government runs high. “We need to meet parents where they are,” Tran says. “Mandates can work, but only if the community trusts the system. In Tennessee, we have work to do on that front.”

A middle-ground approach is to require opt-out rather than opt-in. In opt-out systems, the vaccine is given unless a parent explicitly declines, which has been shown to increase uptake in other states. However, such policies face political hurdles in Tennessee, where parental rights are a sensitive issue. “It's a balancing act,” says a state legislator who has studied the issue. “We want to protect kids, but we also respect parents' authority.”

The question, ultimately, is whether parents will accept the science before their daughters need treatment. For clinicians like Kline, every refusal is a missed opportunity. “I see a 12-year-old in my office, and I know that if I can convince her parent today, I might never see her for a colposcopy at 16,” she says. “But if I fail, she might be back. And the procedure I do then is a lot harder than a shot.”

Disclaimer: This article is for informational purposes only and does not constitute personalized medical advice. Readers should consult their healthcare provider about vaccination decisions.